This inventor holds 3 USPTO granted patents. Top assignee: Genzyme Corporation. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: William Bock: Innovator in Pharmaceutical Chemistry
Introduction
William Bock is a notable inventor based in Bridgewater, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds aimed at treating diseases related to cystic fibrosis. With a total of 3 patents to his name, Bock's work is recognized for its potential impact on medical treatments.
Latest Patents
William Bock's latest patents include innovative formulations of arylamides. One of his patents focuses on heterocyclic compounds and their pharmaceutically acceptable salts, which are crucial for creating effective pharmaceutical preparations. These compounds are designed to treat diseases and conditions mediated by deficient CFTR activity, specifically targeting cystic fibrosis. Another patent details substituted aryl amide compounds, which also aim to address the same medical challenges.
Career Highlights
Bock is currently associated with Genzyme Corporation, a leading biotechnology company known for its focus on rare diseases and innovative therapies. His work at Genzyme has allowed him to explore and develop new pharmaceutical solutions that can significantly improve patient outcomes.
Collaborations
William Bock has collaborated with esteemed colleagues in his field, including Zhongli Gao and Hans Peter Nestler. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic compounds.
Conclusion
William Bock's contributions to pharmaceutical chemistry, particularly in the area of cystic fibrosis treatment, highlight his innovative spirit and dedication to improving healthcare. His patents reflect a commitment to advancing medical science and providing new hope for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
